J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study
- Posted on May 31, 2026
- By AOL
- 0 Views
- 1 min read
J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study
May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the risk of disease progression or death, according to data from a late-stage trial presented on Sunday. The study, which followed patients for over five years, found that those who received the regimen were nine times more likely to have little to no detectable cancer in the prostate at
